Withdrawing amantadine in dyskinetic patients with Parkinson disease : The AMANDYSK trial

Neurology

Volumn 82, Issue 4, 2014, Pages 300-307

  Ory Magne, Fabienne ^a,b   Corvol, Jean Christophe ^c,d,e   Azulay, Jean Philippe ^f   Bonnet, Anne Marie ^c,d   Brefel Courbon, Christine ^a,b,g,h   Damier, Philippe ⁱ   Dellapina, Estelle ^a   Destée, Alain ^j   Durif, Franck ^k   Galitzky, Monique ^a   Lebouvier, Thibaud ⁱ   Meissner, Wassilios ^l   Thalamas, Claire ^a,g   Tison, François ^l   Salis, Alexandrine ^a   Sommet, Agnès ^g   Viallet, François ^m   Vidailhet, Marie ^c,d,e   Rascol, Olivier ^a,b,g,h  

^a Clinical Investigation Center 9201   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^f TIMONE HOSPITAL   (France)

^g University of Medicine   (France)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^l BORDEAUX UNIVERSITY HOSPITAL   (France)

^m Pays d'Aix Hospital   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LEVODOPA; PLACEBO;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; APATHY; ARTICLE; ASTHENIA; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSKINESIA; FALLING; FATIGUE; FLUSHING; GAIT DISORDER; HUMAN; IMPULSE CONTROL DISORDER; INTERVERTEBRAL DISK HERNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARALLEL DESIGN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SWEAT; TREATMENT DURATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84894662888     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000050     Document Type: Article

References (40)

1. Gottwald MD, Aminoff MJ. Therapies for dopaminergicinduced dyskinesias in Parkinson disease. Ann Neurol 2011;69:919-927.
2. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010;24:119-129.
3. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8:67-81.
4. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
5. Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson's disease on quality of life and healthrelated costs: A prospective European study. Eur J Neurol 2005;12:956-963.
6. Olanow W, Schapira AH, Rascol O. Continuous dopaminereceptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23(suppl 10):S117-S126.
7. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: Filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-1117.
8. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008;7:927-938.
9. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46: 1551-1556.
10. da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005; 11:449-452.
11. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levodopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov Disord 2001;16:515-520.
12. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(suppl 3):S2-S41.
13. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011;26: 1072-1082.
14. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
15. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 2005;365: 947-954.
16. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:141-143.
17. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010;25:1357-1363.
18. Réseau Ns-Park: Réseau Neurosciences Parkinson et mouvements anormaux. Available at: Http://www.reseaucic-parkinson.inserm.fr/. Accessed December 19, 2013.
19. Le Centre d'Investigation Clinique du CHU de Purpan recherche des volontaires. Available at: Http://www. chu-toulouse.fr/le-centre-d- investigation-clinique. Accessed December 19, 2013.
20. Le programme hospitalier de recherche clinique (PHRC). Available at: Http://www.sante.gouv.fr/le-programmehospitalier-de-recherche-clinique-phrc. html. Accessed December 19, 2013.
21. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(suppl 3):S580-S584.
22. Van Reekum R, Bayley M, Garner S, et al. N of 1 study: Amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
23. Zifko UA. Management of fatigue in patients with multiple sclerosis. Drugs 2004;64:1295-1304.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
25. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389.
26. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
27. Fahn S, Elton R; Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information; 1987:153-163.
28. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A doubleblind placebo-controlled trial.Mov Disord 2007;22:179-186.
29. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health, Education, and Welfare; 1976:534-537.
30. Durif F, Vidailhet M, Debilly B, Agid Y. Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord 1999;14:242-245.
31. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
32. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: Assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002;17:1099-1105.
33. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
34. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebocontrolled study. Neurology 2004;62:381-388.
35. Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62.
36. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
37. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study. Brain 2000; 123(pt 11):2297-2305.
38. Colosimo C, Martinez-Martin P, Fabbrini G, et al. Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Mov Disord 2010; 25:1131-1142.
39. Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov Disord 2008;23:2398-2403.
40. Goetz CG, Stebbins GT, Chung KA, et al. Which dyskinesia scale best detects treatment response? Mov Disord 2013;28:341-346.